About Evox Therapeutics
Evox Therapeutics is a company based in Oxford (United Kingdom) founded in 2016 by Samir El Andaloussi, Matthew Wood, and Per Lundin.. Evox Therapeutics has raised $155.79 million across 6 funding rounds from investors including Gov.uk, TD Securities and Gates Foundation. The company has 58 employees as of December 31, 2024. Evox Therapeutics offers products and services including ExoEdit Technology and Therapeutics Pipeline. Evox Therapeutics operates in a competitive market with competitors including Harmony Biosciences, QurAlis, Passage Bio, Longboard Pharmaceutical and Autobahn Therapeutics, among others.
- Headquarter Oxford, United Kingdom
- Employees 58 as on 31 Dec, 2024
- Founders Samir El Andaloussi, Matthew Wood, Per Lundin
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Evox Therapeutics Limited
- Date of Incorporation 22 Mar, 2016
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
$11.46 M (USD)29as on Dec 31, 2023
-
Net Profit
$-15.11 M (USD)11as on Dec 31, 2024
-
EBITDA
$-18.81 M (USD)14as on Dec 31, 2024
-
Total Equity Funding
$155.79 M (USD)
in 6 rounds
-
Latest Funding Round
$95.97 M (USD), Series C
Feb 16, 2021
-
Investors
Gov.uk
& 11 more
-
Employee Count
58
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Evox Therapeutics
Evox Therapeutics offers a comprehensive portfolio of products and services, including ExoEdit Technology and Therapeutics Pipeline. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers CRISPR-based gene editing via exosomes for disease treatment
Advances therapies for neurological diseases through exosome nanoparticles
Unlock access to complete
Senior Team
9 people
Leadership Team
7 people
Scientific Team
6 people
Research Team
4 people
Board Team
3 people
Product Management Team
3 people
Human Resources and Administration
2 people
Principal Team
2 people
Unlock access to complete
Funding Insights of Evox Therapeutics
Evox Therapeutics has successfully raised a total of $155.79M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $95.97 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $96.0M
-
First Round
First Round
(07 Apr 2016)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Series C - Evox Therapeutics | Valuation | Redmile Group | |
| Mar, 2019 | Amount | Grant - Evox Therapeutics | Valuation |
investors |
|
| Dec, 2018 | Amount | Series B - Evox Therapeutics | Valuation | Gates Foundation |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Evox Therapeutics
Evox Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, TD Securities and Gates Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Investment management services for science ventures are provided in Oxford.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Evox Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Evox Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Evox Therapeutics Comparisons
Competitors of Evox Therapeutics
Evox Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harmony Biosciences, QurAlis, Passage Bio, Longboard Pharmaceutical and Autobahn Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for rare neurological diseases
|
|
| domain | founded_year | HQ Location |
Drugs and CSF devices are developed for ALS treatment.
|
|
| domain | founded_year | HQ Location |
Gene therapies for CNS rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for rare neurological diseases are developed.
|
|
| domain | founded_year | HQ Location |
CNS therapeutics are developed via regenerative medicine for disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Evox Therapeutics
Frequently Asked Questions about Evox Therapeutics
When was Evox Therapeutics founded?
Evox Therapeutics was founded in 2016.
Where is Evox Therapeutics located?
Evox Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Who is the current CEO of Evox Therapeutics?
Per Lundin is the current CEO of Evox Therapeutics. They have also founded this company.
Is Evox Therapeutics a funded company?
Evox Therapeutics is a funded company, having raised a total of $155.79M across 6 funding rounds to date.
How many employees does Evox Therapeutics have?
As of Dec 31, 2024, the latest employee count at Evox Therapeutics is 58.
What is the annual revenue of Evox Therapeutics?
Annual revenue of Evox Therapeutics is $11.46M as on Dec 31, 2023.
What does Evox Therapeutics do?
Evox Therapeutics was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector. Exosome-based therapies are developed to address neurological diseases through a proprietary CRISPRCas gene editing system encapsulated in exosomes. Genes such as ATXN2, linked to Spinocerebellar Ataxia type 2 and Amyotrophic Lateral Sclerosis, and MSH3, associated with Huntingtons disease and triplet repeat disorders, are targeted in the pipeline. Operations focus on gene modification for neurodegenerative conditions.
Who are the top competitors of Evox Therapeutics?
Evox Therapeutics's top competitors include Harmony Biosciences, QurAlis and MindMed.
What products or services does Evox Therapeutics offer?
Evox Therapeutics offers ExoEdit Technology and Therapeutics Pipeline.
Who are Evox Therapeutics's investors?
Evox Therapeutics has 12 investors. Key investors include Gov.uk, TD Securities, Gates Foundation, Orbimed, and Oxford University Innovation.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.